AiRato Enters into Exclusive Overseas Distribution Agreement with Sumitomo Corporation
AiRato Inc. is pleased to announce that it has entered into an exclusive overseas distribution agreement with Sumitomo Corporation.
Under this partnership, AiRato will work to ensure regulatory compliance across Asian markets, with the goal of launching international sales of its AI-powered treatment planning software starting in 2026.
Background of This Initiative
At AiRato, we have long been engaged in the development of AI-powered treatment planning software, aiming to improve therapeutic outcomes and streamline operations in the field of radiation therapy—particularly in intensity-modulated radiation therapy (IMRT), which requires high precision.
As the aging population increases, radiation therapy is gaining attention due to its minimal physical burden on patients. IMRT, in particular, has demonstrated significant effectiveness. However, its broader adoption continues to face challenges, such as variability in treatment quality and a shortage of medical personnel.
We believe that our AI software addresses these challenges and holds the potential to be utilized not only in Japan but globally. While accelerating our efforts toward domestic market approval, we have also been preparing for global expansion.
Through our newly established partnership with Sumitomo Corporation—an organization with a strong global presence and experience in advancing medical technology businesses—we aim to leverage their network and operational capabilities to first enter the Asian market.
This collaboration marks a major step toward the international deployment of our technology and, more importantly, our mission to deliver better care to more cancer patients worldwide.
(Yuri Kimura and Tomoyuki Kakutani, Co-Founders and CEOs of AiRato Inc.)
Through our partnership with Sumitomo Corporation, we will further strengthen our contribution to patients by providing our AI-powered treatment planning software to medical institutions both in Japan and overseas.